<DOC>
	<DOC>NCT01127893</DOC>
	<brief_summary>An evaluation of the long term safety of tanezumab when administered by subcutaneous injection every 8 weeks for up to 64 weeks</brief_summary>
	<brief_title>Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis</brief_title>
	<detailed_description>This study was terminated on 29 September 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Must have participated in specific Phase 3 parent study Failed screening for parent study, pregnant women, lactating mothers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatic Diseases</keyword>
</DOC>